Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients.

@article{Roth1994EffectsOR,
  title={Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients.},
  author={David Roth and R. D. Smith and Gerald Schulman and Theodore I. Steinman and Fred E. Hatch and Michael R. Rudnick and James Sloand and Barry I. Freedman and Winfred W Williams and Craig A. Shadur},
  journal={American journal of kidney diseases : the official journal of the National Kidney Foundation},
  year={1994},
  volume={24 5},
  pages={
          777-84
        }
}
  • D. Roth, R. Smith, C. Shadur
  • Published 1 November 1994
  • Medicine, Biology
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
View on PubMed
doi.org
164 Citations
Highly Influential Citations
3
Background Citations
32
Methods Citations
4
Results Citations
5

164 Citations

Citation Type

Citation Type

Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients.
TLDR
This study affords conclusive evidence that rHuEpo therapy did not result in accelerated progression of CRF in any treated predialysis patients, nor deleterious increase in blood pressure, but instead resulted in significant slowing of progression and substantial retardation of maintenance dialysis.
Renal function in predialysis children with chronic renal failure treated with erythropoietin
TLDR
It is suggested that in most children with predialysis chronic renal failure long-term administration of EPO is not associated with accelerated deterioration but rather with delayed deterioration of renal function.
Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease
TLDR
The study results suggest that hyporesponsiveness to ESA after the first 12-week administration as well as after 12 weeks is a risk for RD in pre-dialysis CKD patients.
Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis.
  • J. Cody, E. Hodson
  • Medicine, Biology
    The Cochrane database of systematic reviews
  • 2016
TLDR
Treatment with rHuEPO in predialysis patients corrects anaemia, avoids the requirement for blood transfusions and also improves quality of life and exercise capacity, and is not associated with an increased incidence of adverse events.
Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients
TLDR
Epoetin beta, darbepoetin alfa, and epoet in beta pegol are effective and well-tolerated agents for managing anemia in Japanese pre-dialysis CKD patients.
Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients.
  • D. Revicki, R. Brown, R. Benz
  • Medicine, Psychology
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 1995
Uncertain Renoprotective Effect of Erythropoiesis Stimulating Agent in Predialysis Patients
TLDR
It is concluded that renoprotective effect of ESA in CKD stage 4 to 5 patients remains uncertain, and a beneficial trend seems to be noted.
Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial.
TLDR
Early initiation of erythropoietin in predialysis patients with non-severe anemia significantly slows the progression of renal disease and delays the initiation of renal replacement therapy.
Erythropoietin therapy may retard progression in chronic renal transplant dysfunction.
  • B. Becker, Y. Becker, G. Leverson, D. Heisey
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2002
TLDR
The data in a group of renal transplant recipients with chronic allograft dysfunction reinforce data from the CKD realm suggesting that erythropoietin may be of benefit in slowing the rate of loss of function over time.
Effect of early correction of anemia on the progression of CKD.
  • J. Rossert, A. Levin, W. McClellan
  • Medicine, Biology
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2006
TLDR
The data suggest that normalization of hemoglobin levels in patients with CKD is safe and longer duration studies are needed to clarify efficacy benefits with high hemoglobin Levels.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients.
TLDR
The effects of r-HuEPO on renal and systemic hemodynamics and the progression of renal disease were studied in predialysis chronic renal failure patients and the slope of l/serum creatinine with time did not worsen in any patient.
Effect of recombinant human erythropoietin on renal function in humans.
TLDR
It appeared that neither r-HuEPO administration nor a normal hematocrit accelerated the deterioration of renal function in these patients with renal insufficiency.
Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin.
Treatment of the anemia of progressive renal failure with recombinant human erythropoietin.
TLDR
It is concluded that erythropoietin therapy is effective in correcting the anemia of patients with progressive renal failure without affecting renal function, although it may be associated with an increase in blood pressure.
Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial.
TLDR
Recombinant human erythropoietin is effective and safe in ameliorating the anemia of pre-dialysis patients and dose-dependent rise in hematocrit is shown in subjects who received active r-HuEPO.
The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial.
Treatment of the Anemia of Predialysis Patients with Recombinant Human Erythropoietin: A Randomized, Placebo‐Controlled Trial
TLDR
Recombinant human erythropoietin is an effective and potent treatment of anemia caused by renal failure androw studies revealed increases in erythroid, megakaryocyte, and granulocyte-monocyte progenitor cells in patients on r-HuEPO, but no mutagenic effects were seen.
The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency.
Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
TLDR
Hemoglobin remained stable at a mean dose of 199 +/- 139 U/kg of r-HuEPO per week during the maintenance phase, and blood pressure did not increase, but in nine of eighteen previously hypertensive patients antihypertensive medication was increased.
Effect of recombinant human erythropoietin on muscle energy metabolism in patients with end-stage renal disease: a 31P-nuclear magnetic resonance spectroscopic study.
...
1
2
3
...